Protection provided by a recombinant ALVAC®-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain

Minke, J.M.; Siger, L.; Cupillard, Lionel; Powers, Barbara E.; Bakonyi, Tamás; Bøyum, S; Nowotny, Norbert; Bowen, Richard A.

doi:10.1016/j.vaccine.2011.04.058

Cited by 42 publications

(34 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, single dose vaccines are desirable, especially for application during outbreaks, in vaccination campaigns in poorly industrialized countries or for wild animals. In addition to this, the recent epidemiologic scenario of WNV has highlighted the need for verifying the efficacy of available vaccines against viruses from lineages 1 and 2 [57], [58], [59]. Having in mind these considerations, the protection conferred by immunization with our WNV RSPs against lethal challenge with WNV virulent strains from both lineages was investigated.…”

Section: Discussionmentioning

confidence: 99%

Protection of a Single Dose West Nile Virus Recombinant Subviral Particle Vaccine against Lineage 1 or 2 Strains and Analysis of the Cross-Reactivity with Usutu Virus

et al. 2014

View full text Add to dashboard Cite

West Nile virus (WNV) is a neurovirulent mosquito-borne flavivirus. High WNV virulence was mainly associated with lineage 1 strains, but recent outbreaks have unveiled circulation of highly virulent lineage 2 strains. Co-expression of flavivirus prM and E glycoproteins drives the assembly of recombinant subviral particles (RSPs) that share antigenic features with virions. Mouse immunization with lineage 1 WNV RSPs induced a potent humoral response against WNV with production of neutralizing antibodies. A single inoculation of RSPs formulated with Al(OH)3 as adjuvant protected mice against a lethal challenge with WNV strains from lineage 1 or 2. The cross-reactivity of the response elicited by these RSPs was analyzed against the related flavivirus Usutu virus (USUV), which shares multiple ecological and antigenic features with WNV. Immunization with WNV-RSPs increased specific, although low, antibody titers found upon subsequent USUV infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Protection of a Single Dose West Nile Virus Recombinant Subviral Particle Vaccine against Lineage 1 or 2 Strains and Analysis of the Cross-Reactivity with Usutu Virus

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Horses that received two doses and that were challenged 1 year postvaccination showed markedly reduced WNV viremia, affecting just 5% of immunized horses but 82% of controls (9). An alternative equine WNV vaccine is based on a live chimeric canary poxvirus vector carrying the WNV membrane (prM) and envelope (E) proteins (10)(11)(12). Yet another equine live chimeric WNV vaccine, made from insertion of prM and E genes into the yellow fever virus backbone (PreveNile/Intervet) (11,13), was recalled in 2010 due to severe vaccine adverse events, including deaths (14), but was subsequently rereleased as an inactivated vaccine.…”

mentioning

confidence: 99%

An Inactivated Cell Culture Japanese Encephalitis Vaccine (JE-ADVAX) Formulated with Delta Inulin Adjuvant Provides Robust Heterologous Protection against West Nile Encephalitis via Cross-Protective Memory B Cells and Neutralizing Antibody

Petrovsky

Larena

Siddharthan

et al. 2013

J Virol

View full text Add to dashboard Cite

e West Nile virus (WNV), currently the cause of a serious U.S. epidemic, is a mosquito-borne flavivirus and member of the Japanese encephalitis (JE) serocomplex. There is currently no approved human WNV vaccine, and treatment options remain limited, resulting in significant mortality and morbidity from human infection. Given the availability of approved human JE vaccines, this study asked whether the JE-ADVAX vaccine, which contains an inactivated cell culture JE virus antigen formulated with Advax delta inulin adjuvant, could provide heterologous protection against WNV infection in wild-type and ␤2-microglobulindeficient (␤2m ؊/؊ ) murine models. Mice immunized twice or even once with JE-ADVAX were protected against lethal WNV challenge even when mice had low or absent serum cross-neutralizing WNV titers prior to challenge. Similarly, ␤2m ؊/؊ mice immunized with JE-ADVAX were protected against lethal WNV challenge in the absence of CD8 ؉ T cells and prechallenge WNV antibody titers. Protection against WNV could be adoptively transferred to naive mice by memory B cells from JE-ADVAX-immunized animals. Hence, in addition to increasing serum cross-neutralizing antibody titers, JE-ADVAX induced a memory Bcell population able to provide heterologous protection against WNV challenge. Heterologous protection was reduced when JE vaccine antigen was administered alone without Advax, confirming the importance of the adjuvant to induction of cross-protective immunity. In the absence of an approved human WNV vaccine, JE-ADVAX could provide an alternative approach for control of a major human WNV epidemic.

show abstract

“…Horses are considered as dead-end hosts for WNV due to the short and low magnitude viremia observed following infected mosquito bites. A maximum serum virus titer of 10 3 pfu/ml and viremia duration of 6 days have been demonstrated to occur in experimental equine infections with WNV, which is unlikely to initiate an infection in the midgut epithelia of the mosquito vector [29], [34], [35]. Since RNA levels detected via rRT-PCR in positive equine plasma this study are low and roughly correspond to the levels noted in experimental infections, it can be assumed that they do not significantly contribute to the virus lifecycle by infecting vectors.…”

Section: Discussionmentioning

confidence: 99%

Serological, Molecular and Entomological Surveillance Demonstrates Widespread Circulation of West Nile Virus in Turkey

et al. 2014

View full text Add to dashboard Cite

West Nile virus (WNV), a mosquito-borne flavivirus with significant impact on human and animal health, has recently demonstrated an expanded zone of activity globally. The aim of this study is to investigate the frequency and distribution of WNV infections in potential vectors and several mammal and avian species in Turkey, where previous data indicate viral circulation. The study was conducted in 15 provinces across Turkey during 2011–2013. In addition, the entomological study was extended to 4 districts of the Turkish Republic of Northern Cyprus. WNV exposure was determined in humans, horses, sheep and ducks from Mersin, Sanliurfa, Van and Kars provinces of Turkey, via the detection of neutralizing antibodies. WNV RNA was sought in human and equine samples from Mersin, Adana and Mugla provinces. Field-collected mosquitoes from 92 sites at 46 locations were characterized morphologically and evaluated for viral RNA. Neutralizing antibodies were identified in 10.5% of the 1180 samples studied and detected in all species evaluated. Viral nucleic acids were observed in 5.9% of 522 samples but only in horses. A total of 2642 mosquito specimens belonging to 15 species were captured, where Ochlerotatus caspius (52.4%), Culex pipiens sensu lato (24.2%) comprise the most frequent species. WNV RNA was detected in 4 mosquito pools (1.9%), that comprise Oc. caspius Cx. pipiens s.l. and DNA barcoding revealed the presence of Cx. quinquefasciatus and Cx. perexiguus mosquitoes in infected Culex pools. All WNV partial sequences were characterized as lineage 1 clade 1a. These findings indicate a widespread WNV activity in Turkey, in Eastern Thrace and Mediterranean-Aegean regions as well as Southeastern and Northeastern Anatolia.

show abstract

Protection provided by a recombinant ALVAC®-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain

Cited by 42 publications

References 16 publications

Protection of a Single Dose West Nile Virus Recombinant Subviral Particle Vaccine against Lineage 1 or 2 Strains and Analysis of the Cross-Reactivity with Usutu Virus

Protection of a Single Dose West Nile Virus Recombinant Subviral Particle Vaccine against Lineage 1 or 2 Strains and Analysis of the Cross-Reactivity with Usutu Virus

An Inactivated Cell Culture Japanese Encephalitis Vaccine (JE-ADVAX) Formulated with Delta Inulin Adjuvant Provides Robust Heterologous Protection against West Nile Encephalitis via Cross-Protective Memory B Cells and Neutralizing Antibody

Serological, Molecular and Entomological Surveillance Demonstrates Widespread Circulation of West Nile Virus in Turkey

Contact Info

Product

Resources

About